FY2024 EPS Estimate for Hims & Hers Health Raised by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Analysts at Seaport Res Ptn raised their FY2024 earnings per share (EPS) estimates for shares of Hims & Hers Health in a research note issued on Monday, November 4th. Seaport Res Ptn analyst A. Kessler now expects that the company will post earnings per share of $0.25 for the year, up from their previous forecast of $0.23. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.22 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health's FY2025 earnings at $0.51 EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The company's revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the company earned ($0.04) EPS.

Several other equities research analysts have also issued reports on the company. Bank of America raised their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday. Imperial Capital lowered Hims & Hers Health from an "outperform" rating to an "in-line" rating in a research note on Friday, August 9th. Piper Sandler reissued a "neutral" rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target for the company. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.00.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $0.20 during trading on Thursday, hitting $23.62. The company had a trading volume of 13,261,955 shares, compared to its average volume of 8,640,148. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 54.80 and a beta of 1.06. Hims & Hers Health has a one year low of $6.58 and a one year high of $25.74. The company has a fifty day simple moving average of $18.40 and a two-hundred day simple moving average of $18.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company's stock worth $221,379,000 after buying an additional 136,907 shares during the last quarter. Renaissance Technologies LLC lifted its position in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the period. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company's stock worth $25,928,000 after acquiring an additional 1,634,000 shares during the period. Bank of New York Mellon Corp lifted its position in Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company's stock worth $13,701,000 after acquiring an additional 273,473 shares during the period. Finally, M&G Plc acquired a new stake in Hims & Hers Health during the 1st quarter worth about $8,232,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,345 shares of Hims & Hers Health stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the transaction, the insider now directly owns 159,796 shares in the company, valued at approximately $2,341,011.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the business's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 2,345 shares of the business's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the transaction, the insider now owns 159,796 shares in the company, valued at approximately $2,341,011.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 854,547 shares of company stock worth $15,987,230 in the last ninety days. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.